Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats

Alvin V. Terry, M. Gattu, J. J. Buccafusco, J. W. Sowell, J. W. Kosh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The purpose of this study was to evaluate potential cognitive effects and nicotinic receptor binding affinity of a ranitidine analog previously found to antagonize M2 muscarinic-cholinergic receptors and acetylcholinesterase (ACHE) in vitro. Several doses of JWS-USC-751X (JWS) were evaluated in rats in three memory-related tasks, a passive avoidance (PA) paradigm, the Morris Water Maze (MWM), and a delayed stimulus discrimination task (DSDT). Rat groups (n per dose) were as follows: PA = Wistar, n = 2025; MWM = 1-year-old Long-Evans, n = 7-8; and DSDT, Wistar, n = 6. In PA, JWS (1.0 mg/kg) improved scopolamine (SCOP)-induced deficits in learning to avoid an unsafe region of a shuttle box as indicated by both latency and learning frequency analysis. In the MWM, JWS (0.1, 0.5, and 1.0 mg/kg) improved 'spatial navigation learning' as demonstrated by the improved ability of rats to locate a hidden platform on day 2 of an 8-day training schedule. Two doses (0.1 and 0.5 mg/kg) also improved 'spatial bias' for the previous platform location when tested on day 9. JWS was not particularly effective at reducing SCOP-induced deficits in the MWM and failed to improve DSDT accuracy in a dose-dependent manner across delays. However, repeated optimal doses significantly improved DSDT accuracy at medium and long, presumably more difficult, delay intervals. JWS did not demonstrate a high affinity at nicotinic receptors as indicated in [3H]cytisine displacement assays. The data thus indicate moderate improvements in the performance of three memory-related tasks in both young and middle-aged rodents of two strains administered JWS. These results appear to substantiate the hypothesis that antagonizing both M2 cholinergic receptors and AChE offers a potential means of improving cognition and supports the potential use of this agent (or similar compounds) in disorders of memory.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalDrug Development Research
Volume47
Issue number2
DOIs
StatePublished - Jan 1 1999

Fingerprint

Ranitidine
Task Performance and Analysis
Scopolamine Hydrobromide
Water
Nicotinic Receptors
Cholinergic Receptors
Learning
Aptitude
Memory Disorders
Muscarinic Receptors
Acetylcholinesterase
Cognition
Rodentia
Appointments and Schedules
Discrimination (Psychology)

Keywords

  • Acetylcholinesterase
  • Cholinergic
  • Histamine
  • M receptor
  • Memory
  • Rat

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats. / Terry, Alvin V.; Gattu, M.; Buccafusco, J. J.; Sowell, J. W.; Kosh, J. W.

In: Drug Development Research, Vol. 47, No. 2, 01.01.1999, p. 97-106.

Research output: Contribution to journalArticle

Terry, Alvin V. ; Gattu, M. ; Buccafusco, J. J. ; Sowell, J. W. ; Kosh, J. W. / Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats. In: Drug Development Research. 1999 ; Vol. 47, No. 2. pp. 97-106.
@article{1a88a762e7924745979c1f0e25cb75a5,
title = "Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats",
abstract = "The purpose of this study was to evaluate potential cognitive effects and nicotinic receptor binding affinity of a ranitidine analog previously found to antagonize M2 muscarinic-cholinergic receptors and acetylcholinesterase (ACHE) in vitro. Several doses of JWS-USC-751X (JWS) were evaluated in rats in three memory-related tasks, a passive avoidance (PA) paradigm, the Morris Water Maze (MWM), and a delayed stimulus discrimination task (DSDT). Rat groups (n per dose) were as follows: PA = Wistar, n = 2025; MWM = 1-year-old Long-Evans, n = 7-8; and DSDT, Wistar, n = 6. In PA, JWS (1.0 mg/kg) improved scopolamine (SCOP)-induced deficits in learning to avoid an unsafe region of a shuttle box as indicated by both latency and learning frequency analysis. In the MWM, JWS (0.1, 0.5, and 1.0 mg/kg) improved 'spatial navigation learning' as demonstrated by the improved ability of rats to locate a hidden platform on day 2 of an 8-day training schedule. Two doses (0.1 and 0.5 mg/kg) also improved 'spatial bias' for the previous platform location when tested on day 9. JWS was not particularly effective at reducing SCOP-induced deficits in the MWM and failed to improve DSDT accuracy in a dose-dependent manner across delays. However, repeated optimal doses significantly improved DSDT accuracy at medium and long, presumably more difficult, delay intervals. JWS did not demonstrate a high affinity at nicotinic receptors as indicated in [3H]cytisine displacement assays. The data thus indicate moderate improvements in the performance of three memory-related tasks in both young and middle-aged rodents of two strains administered JWS. These results appear to substantiate the hypothesis that antagonizing both M2 cholinergic receptors and AChE offers a potential means of improving cognition and supports the potential use of this agent (or similar compounds) in disorders of memory.",
keywords = "Acetylcholinesterase, Cholinergic, Histamine, M receptor, Memory, Rat",
author = "Terry, {Alvin V.} and M. Gattu and Buccafusco, {J. J.} and Sowell, {J. W.} and Kosh, {J. W.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1002/(SICI)1098-2299(199906)47:2<97::AID-DDR5>3.0.CO;2-I",
language = "English (US)",
volume = "47",
pages = "97--106",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats

AU - Terry, Alvin V.

AU - Gattu, M.

AU - Buccafusco, J. J.

AU - Sowell, J. W.

AU - Kosh, J. W.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The purpose of this study was to evaluate potential cognitive effects and nicotinic receptor binding affinity of a ranitidine analog previously found to antagonize M2 muscarinic-cholinergic receptors and acetylcholinesterase (ACHE) in vitro. Several doses of JWS-USC-751X (JWS) were evaluated in rats in three memory-related tasks, a passive avoidance (PA) paradigm, the Morris Water Maze (MWM), and a delayed stimulus discrimination task (DSDT). Rat groups (n per dose) were as follows: PA = Wistar, n = 2025; MWM = 1-year-old Long-Evans, n = 7-8; and DSDT, Wistar, n = 6. In PA, JWS (1.0 mg/kg) improved scopolamine (SCOP)-induced deficits in learning to avoid an unsafe region of a shuttle box as indicated by both latency and learning frequency analysis. In the MWM, JWS (0.1, 0.5, and 1.0 mg/kg) improved 'spatial navigation learning' as demonstrated by the improved ability of rats to locate a hidden platform on day 2 of an 8-day training schedule. Two doses (0.1 and 0.5 mg/kg) also improved 'spatial bias' for the previous platform location when tested on day 9. JWS was not particularly effective at reducing SCOP-induced deficits in the MWM and failed to improve DSDT accuracy in a dose-dependent manner across delays. However, repeated optimal doses significantly improved DSDT accuracy at medium and long, presumably more difficult, delay intervals. JWS did not demonstrate a high affinity at nicotinic receptors as indicated in [3H]cytisine displacement assays. The data thus indicate moderate improvements in the performance of three memory-related tasks in both young and middle-aged rodents of two strains administered JWS. These results appear to substantiate the hypothesis that antagonizing both M2 cholinergic receptors and AChE offers a potential means of improving cognition and supports the potential use of this agent (or similar compounds) in disorders of memory.

AB - The purpose of this study was to evaluate potential cognitive effects and nicotinic receptor binding affinity of a ranitidine analog previously found to antagonize M2 muscarinic-cholinergic receptors and acetylcholinesterase (ACHE) in vitro. Several doses of JWS-USC-751X (JWS) were evaluated in rats in three memory-related tasks, a passive avoidance (PA) paradigm, the Morris Water Maze (MWM), and a delayed stimulus discrimination task (DSDT). Rat groups (n per dose) were as follows: PA = Wistar, n = 2025; MWM = 1-year-old Long-Evans, n = 7-8; and DSDT, Wistar, n = 6. In PA, JWS (1.0 mg/kg) improved scopolamine (SCOP)-induced deficits in learning to avoid an unsafe region of a shuttle box as indicated by both latency and learning frequency analysis. In the MWM, JWS (0.1, 0.5, and 1.0 mg/kg) improved 'spatial navigation learning' as demonstrated by the improved ability of rats to locate a hidden platform on day 2 of an 8-day training schedule. Two doses (0.1 and 0.5 mg/kg) also improved 'spatial bias' for the previous platform location when tested on day 9. JWS was not particularly effective at reducing SCOP-induced deficits in the MWM and failed to improve DSDT accuracy in a dose-dependent manner across delays. However, repeated optimal doses significantly improved DSDT accuracy at medium and long, presumably more difficult, delay intervals. JWS did not demonstrate a high affinity at nicotinic receptors as indicated in [3H]cytisine displacement assays. The data thus indicate moderate improvements in the performance of three memory-related tasks in both young and middle-aged rodents of two strains administered JWS. These results appear to substantiate the hypothesis that antagonizing both M2 cholinergic receptors and AChE offers a potential means of improving cognition and supports the potential use of this agent (or similar compounds) in disorders of memory.

KW - Acetylcholinesterase

KW - Cholinergic

KW - Histamine

KW - M receptor

KW - Memory

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0344758441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344758441&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2299(199906)47:2<97::AID-DDR5>3.0.CO;2-I

DO - 10.1002/(SICI)1098-2299(199906)47:2<97::AID-DDR5>3.0.CO;2-I

M3 - Article

AN - SCOPUS:0344758441

VL - 47

SP - 97

EP - 106

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 2

ER -